The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2.
Systemic administration of interleukin-2 (IL-2) in humans may induce antibodies specific to IL-2. The case is reported of a patient with metastatic rectal carcinoma who was treated with long-term subcutaneous IL-2 and a combination of subcutaneous IL-2 and interferon-alpha 2b (IFN-alpha 2b). This patient developed nonneutralizing and neutralizing anti-IL-2 antibodies recognizing both the recombinant and natural cytokine. Detectable serum levels of neutralizing antibodies were accompanied by the inhibition of immune responsiveness to systemic IL-2 in vivo.
Kirchner
H
H
Department of Hematology & Oncology, MHH University Medical Center, Hanover, Germany.
Körfer
A
A
Evers
P
P
Szamel
M M
MM
Knüver-Hopf
J
J
Mohr
H
H
Franks
C R
CR
Pohl
U
U
Resch
K
K
Hadam
M
M
D000906:Antibodies / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology*; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012004:Rectal Neoplasms / Q000473:pathology
D000906:Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins